



## Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 06, 2024

### **Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET**

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Oncocyte Corp.](#) (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the "Events & Presentations" section of the Company's website at <https://investors.oncocyte.com>. A replay of the webcast will be available on the Company's website shortly after the conclusion of the call.

### **CONFERENCE CALL DETAILS:**

Participant Toll-Free Dial-In Number: (800) 715-9871

Participant Toll Dial-In Number: +1 (646) 307-1963

Conference ID: 4153469

**WEBCAST DETAILS:** <https://events.q4inc.com/attendee/686764682>

### **About Oncocyte**

Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit <https://oncocyte.com/>.

For more information about our products, please visit the following web pages:

**VitaGraft Kidney™** - <https://oncocyte.com/vitagraft-kidney>/**VitaGraft Liver™** -

<https://oncocyte.com/vitagraft-liver/>

**GraftAssure™** - <https://oncocyte.com/graftassure>/**DetermaIO™** - <https://oncocyte.com/determa-io/>

**DetermaCNI™** - <https://oncocyte.com/determa-cni/>

VitaGraft™, GraftAssure™, DetermalO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

**CONTACT:**

Jeff Ramson

PCG Advisory

(646) 863-6893

[jramson@pcgadvisory.com](mailto:jramson@pcgadvisory.com)



Source: OncoCyte Corporation

